Conference abstract · 30 Jun 2016
Conference abstractPublished 2016
Amorphous solid dispersion (ASD)formulation of the low-solubility drug rifaximine allows overcoming the solubility-permeability tradeoff
Department of Clinical Pharmacology, School of Pharmacy, Faculty of HealthSciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The aim of this work was to assess the efficiency of different rifaximine amorphous solid dispersions (ASDs) in achieving and maintaining supersaturation and to investigate the solubility-permeability interplay when increasing the apparent solubility via ASD formulations. Spray-dried ASDs of rifaximine in different hydrophilic polymers were prepared and their ability to achieve and maintain supersaturation over 24 h was assessed. Then, rifaximine’s apparent intestinal permeability was investigated as a function of increasing supersaturation in-vitro using the parallel artificial membrane permeability assay (PAMPA) model and in-vivo using the single-pass rat intestinal perfusion model. The efficiency of the different ASDs to achieve and maintain supersaturation of rifaximine was found to be highly polymer dependent, and the Copovidone:HPC-SL formulation was found to be superior to the other ASDs, allowing supersaturation of 200× that of the crystalline solubility for over 20 hours. Rifaximine flux across the intestine from supersaturated solutions was increased, and the apparent intestinal permeability was constant, irrespective of the degree of supersaturation. In conclusion, while with other solubility-enabling approaches (e.g., surfactants, cyclodextrins, cosolvents), it is not enough to increase the apparent solubility, but to strike the optimal solubility–permeability balance, which limits the chances for successful drug delivery, the amorphous form emerges as a more advantageous strategy, in which higher apparent solubility (i.e., supersaturation) will be readily translated into higher drug flux and overall absorption.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 18 Jul 2016
The solubility-permeability interplay in Formulation Development for Low-Solubility Drugs
Conference abstract · 7 Mar 2016
An investigation into the stability and aqueous solubility of amorphous solid dispersions of BCS class II drugs
Conference abstract · 17 Aug 2015
Rational design of amorphous solid dispersion for solubility and bioavailability enhancement
Conference abstract
Exemestane solid dispersions: Enhancement of solubility and permeability
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 12 Jun 2025
Melt-in-Mouth Miracles: A New Era of Drug Delivery with Mouth Dissolving Tablets
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Avital Beig”
- BylineArticles whose byline prints “Arik Dahan”

